Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study

International Journal of Cardiology
Susana RavassaJan A Staessen

Abstract

The validation of effective screening tools for the identification of patients with subclinical myocardial remodelling is a major clinical need. Thus, we explored the associations of circulating biomarkers of cardiomyocyte injury and stress with subclinical cardiac remodelling and dysfunction, and with biomarkers reflecting collagen turnover. We randomly recruited 727 subjects from a general population (51.2% women; mean age 51.3 years). Measurements included echocardiographic left atrial (LA) and left ventricular (LV) structure and function, quantification of high sensitivity cardiac Troponin T (hs-cTnT), NT-proBNP, and biomarkers of collagen types I and III turnover. In unadjusted and adjusted analyses, the prevalence of LA enlargement (LAE), LV hypertrophy (LVH) and LV diastolic dysfunction (LVDD) increased with higher hs-cTnT (P ≤ 0.031). NT-proBNP was independently associated with LVDD (P=0.009). Both biomarkers combined yielded significant integrated discrimination and net reclassification improvements (P ≤ 0.014 and P ≤ 0.009, respectively) for LAE, LVH and LVDD, over the conventional risk factors, and were independently and positively associated with biomarkers of collagen type I turnover. In a sensitivity analysis, aft...Continue Reading

References

Aug 3, 2002·Hypertension·M Mitchell LindsayFrancis G Dunn
Jan 9, 2003·JAMA : the Journal of the American Medical Association·Margaret M RedfieldRichard J Rodeheffer
Oct 3, 2003·Journal of the American College of Cardiology·Teresa S M TsangJames B Seward
Sep 29, 2004·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·John S GottdienerUNKNOWN American Society of Echocardiography
Nov 20, 2004·Current Problems in Cardiology·Vijaya K MunagalaMargaret M Redfield
Oct 8, 2009·Circulation. Heart Failure·Tatiana KuznetsovaJan A Staessen
Jan 12, 2010·Circulation. Cardiovascular Imaging·Michel G KhouriMark H Drazner
Feb 9, 2010·Expert Review of Cardiovascular Therapy·Tatiana KuznetsovaJan A Staessen
Apr 14, 2010·Circulation·Begoña LópezJavier Díez
Jul 28, 2010·American Journal of Epidemiology·Tatiana KuznetsovaNilesh J Samani
Dec 9, 2010·JAMA : the Journal of the American Medical Association·James A de LemosDarren K McGuire
Jan 5, 2011·Statistics in Medicine·Michael J PencinaEwout W Steyerberg
Mar 21, 2012·Cardiovascular Ultrasound·Malgorzata Kloch-BadelekUNKNOWN European Project On Genes in Hypertension (EPOGH) Investigators
Jul 12, 2012·European Heart Journal·Sachin GuptaMark H Drazner
Aug 10, 2012·American Journal of Epidemiology·Nancy R Cook
Aug 28, 2012·Journal of the American College of Cardiology·M Adnan NadirAllan D Struthers
May 2, 2014·Journal of the American Heart Association·Tatiana KuznetsovaJan A Staessen

❮ Previous
Next ❯

Citations

Feb 2, 2016·Clinica Chimica Acta; International Journal of Clinical Chemistry·Anna M NordenskjöldBertil Lindahl
Jun 21, 2017·Proceedings of the National Academy of Sciences of the United States of America·Xiaoyang LiHongjie Dai
Feb 22, 2018·Medical Sciences : Open Access Journal·Tom Kai Ming WangGladding Patrick
Sep 11, 2018·European Journal of Preventive Cardiology·Zhen-Yu ZhangJan A Staessen
Sep 20, 2017·Current Medicinal Chemistry·Polychronis DilaverisDimitris Tousoulis
Apr 9, 2017·The International Journal of Cardiovascular Imaging·Tom HendriksPim van der Harst
Jan 15, 2019·Journal of the American Heart Association·Nicholas CauwenberghsTatiana Kuznetsova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Related Papers

Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
Francesca MencarelliGiovanni Montini
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology
Swee Guan TeoTiong Cheng Yeo
American Heart Journal
Zhi You FangThomas H Marwick
© 2021 Meta ULC. All rights reserved